SCHEMBL6006432

SCHEMBL6006432

O=CNCc1cccc2nc3ccccc3cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.47
ALDH1A1 P00352 4/20 0.47
GLA P06280 2/20 0.47
HPGD P15428 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
PTBP1 P26599 1/20 0.47
RCE1 Q9Y256 1/20 0.47
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH7 P40394 1/20 0.44
MEN1 O00255 4/20 0.43
MAPT P10636 2/20 0.42
ACHE P22303 1/20 0.42
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5852422 0.84 HPGD (0.47) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL6006497 0.84 KMT2A (0.47) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL5853811 0.81 HPGD (0.47) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL5852475 0.80 CHRM2 (0.46) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL6006425 0.80 KMT2A (0.46) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL5852498 0.80 CHRM2 (0.46) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL406430 0.80 CA2 (0.54) KMT2AHPGDADH1BADH1CADH1A
SCHEMBL28201815 0.78 ALDH1A1 (0.55) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL9936012 0.78 KMT2A (0.55) KMT2AALDH1A1GLAHPGDKDM4E
SCHEMBL29562242 0.78 ALDH1A1 (0.55) KMT2AALDH1A1GLAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 KMT2A 2387/4885ALDH1A1 228/4885GLA 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.